BioTech Medics, Inc.
BMCS · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 12.92 | 0.23 | -0.19 |
| FCF Yield | 0.00% | -0.37% | -1.01% | -1.34% |
| EV / EBITDA | -1,144.53 | 39.22 | -14.41 | -160.01 |
| Quality | ||||
| ROIC | -0.00% | 0.14% | -0.17% | -0.46% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 4.78 | 0.15 | 0.56 | 0.27 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | -60.37% | 90.89% | -513.63% |
| Safety | ||||
| Net Debt / EBITDA | -0.69 | 0.14 | 0.00 | -0.01 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |